Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aquestive Therapeutics, Inc.
Report date September 03, 2026 · Filed September 08, 2026
Section 16 reporting ended · disclosed 2025-10-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,833 |
Reported balance
After 2026-09-03 transaction · row 2
1 source rowRow 2 · 2026-09-03 · Other · Acquired 4,587 · Balance 206,833 F1: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2027-06-08 | Direct | 0 |
Reported balance
After 2026-09-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-03 · Other · Disposed 4,587 · Balance 0 |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 2,000 |
Reported balance
Holding disclosure · report date 2026-09-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 8, 2026 20:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherWarrant (Right to Buy) · Derivative | 4,587 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001214659-26-011475 · marketforms-73943.xml · derivative · entry 3 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,587 shares Expires 2027-06-08 Read SEC document |
| September 03, 2026 Filed Sep 8, 2026 20:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | OtherCommon Stock | 4,587 | $0.96 | $4,403.52 |
DisclosureSEC source: 0001214659-26-011475 · marketforms-73943.xml · nonDerivative · entry 2 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,833 F1 · shares: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share. F1 · price: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:32 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 72,734 | $4.18 | $304,028.12 |
DisclosureSEC source: 0001214659-26-005748 · marketforms-73070.xml · nonDerivative · entry 2 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,246 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 16:50 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 45,791 | $4.17 | $191,085.84 |
DisclosureSEC source: 0001214659-26-003141 · marketforms-72467.xml · nonDerivative · entry 3 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,980 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.32. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:50 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 42,500 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001214659-26-003141 · marketforms-72467.xml · derivative · entry 4 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2036-03-09 F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 16:50 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-003141 · marketforms-72467.xml · nonDerivative · entry 2 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,771 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 18:01 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001214659-25-015048 · marketforms-71051.xml · derivative · entry 4 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2031-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. F3 · derivative.exercise_date: This option was granted on June 10, 2021 and is fully vested. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 18:01 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 67,575 | $7.01 | $473,700.75 |
DisclosureSEC source: 0001214659-25-015048 · marketforms-71051.xml · nonDerivative · entry 3 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 240,771 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. Read SEC document |
| October 15, 2025 Filed Oct 17, 2025 18:01 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 25,000 | $3.10 | $77,567.50 |
DisclosureSEC source: 0001214659-25-015048 · marketforms-71051.xml · nonDerivative · entry 2 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 23:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001214659-25-013493 · marketforms-70687.xml · derivative · entry 6 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2032-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. F4 · derivative.exercise_date: This option was granted on August 5, 2022 and is fully vested. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 23:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001214659-25-013493 · marketforms-70687.xml · derivative · entry 5 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. F3 · derivative.exercise_date: This option was granted on August 9, 2019 and is fully vested. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 23:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 62,180 | $5.00 | $310,900.00 |
DisclosureSEC source: 0001214659-25-013493 · marketforms-70687.xml · nonDerivative · entry 4 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,346 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 23:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 25,000 | $0.71 | $17,657.50 |
DisclosureSEC source: 0001214659-25-013493 · marketforms-70687.xml · nonDerivative · entry 3 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 345,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 23:06 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Exercise / conversionCommon Stock | 25,000 | $3.15 | $78,750.00 |
DisclosureSEC source: 0001214659-25-013493 · marketforms-70687.xml · nonDerivative · entry 2 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 320,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 2,182 | $2.54 | $5,542.28 |
DisclosureSEC source: 0001214659-25-004227 · marketforms-68571.xml · nonDerivative · entry 5 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,526 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 09, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 7,997 | $2.65 | $21,192.05 |
DisclosureSEC source: 0001214659-25-004227 · marketforms-68571.xml · nonDerivative · entry 4 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 297,708 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001214659-25-004227 · marketforms-68571.xml · derivative · entry 6 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-03-07 F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 7,361 | $2.65 | $19,506.65 |
DisclosureSEC source: 0001214659-25-004227 · marketforms-68571.xml · nonDerivative · entry 3 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,705 F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 21:48 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-25-004227 · marketforms-68571.xml · nonDerivative · entry 2 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,066 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2025 Filed Apr 13, 2026 19:53 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-004595 · marketforms-72927.xml · derivative · entry 1 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-03-07 F1 · security: This Form 4 was filed late due to an inadvertent administrative oversight. F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period). Read SEC document |
| November 26, 2024 Filed Nov 27, 2024 21:24 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | SaleCommon Stock | 44 | $4.87 | $214.06 |
DisclosureSEC source: 0001214659-24-019685 · marketforms-67449.xml · nonDerivative · entry 2 Jung Cassie · CIK 0001960154 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Indirect · by spouse IRA Disclosed balance after: 0 F1 · shares: Shares owned by spouse who shares Ms. Jung's household. Ms. Jung disclaims beneficial ownership of the shares held by her spouse, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16(a) of the Securities Exchange Act of 1940, as amended, or for any other purpose. Read SEC document |
| March 10, 2024 Filed Mar 12, 2024 17:46 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 1,132 | $4.88 | $5,524.16 |
DisclosureSEC source: 0001214659-24-004390 · marketforms-65150.xml · nonDerivative · entry 4 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,754 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 17:46 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 8,300 | $4.88 | $40,504.00 |
DisclosureSEC source: 0001214659-24-004390 · marketforms-65150.xml · nonDerivative · entry 3 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,886 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. Read SEC document |
| March 09, 2024 Filed Oct 2, 2024 18:14 UTC Amendment | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 14,120 | $4.88 | $68,905.60 |
DisclosureSEC source: 0001214659-24-017008 · marketforms-67098.xml · nonDerivative · entry 3 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,066 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. This amended Form 4 is being filed to revise the number of shares withheld by the issuer to satisfy tax withholding obligations originally reported on form 4 filed on March 12, 2024 . Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,625 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001214659-24-004304 · marketforms-65134.xml · derivative · entry 5 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,625 Underlying: Common Stock · 50,625 shares Expires 2024-03-07 F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| March 07, 2024 Filed Mar 11, 2024 14:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 101,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-004304 · marketforms-65134.xml · nonDerivative · entry 4 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,186 F3 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:30 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-010920 · marketforms-61883.xml · derivative · entry 1 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| May 05, 2023 Filed May 5, 2023 20:00 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantPerformance Stock Units · Derivative | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-006554 · marketforms-61238.xml · derivative · entry 1 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2026-05-05 F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period. Read SEC document |
| March 10, 2023 Filed Mar 11, 2024 14:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | Tax withholdingCommon Stock | 1,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-24-004304 · marketforms-65134.xml · nonDerivative · entry 3 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,936 F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person. F2 · balance_after: The original Form 3, filed on 1/1/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares vested that occurred on 3/10/22 as a total of 4,663 shares vested and owned when in fact 3,173 shares of the Issuer's common stock were owned, net of taxes withheld. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects a reduction in the number of shares reported as beneficially owned by the reporting person by 1,490 shares reflecting share withheld for the payment of taxes. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 20:07 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-23-003693 · marketforms-59531.xml · nonDerivative · entry 1 Jung Cassie · CIK 0001960154 · SVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,747 F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.